12 results about "Cefotaxime" patented technology

This invention provides a polypeptide comprising the sequence shown in any one of SEQ ID NO:1-8. It also provides a composition comprising the polypeptide with the sequence shown in SEQ ID NO:7, cefotaxime, and sulbactam. The polypeptide with the sequence SEQ ID NO:7 exhibits strong inhibitory activity against *Escherichia coli* or *Listeria monocytogenes*. When used in combination with cefotaxime and sulbactam, this polypeptide exhibits strong inhibitory activity against β-lactamase-producing *Escherichia coli*. Therefore, the polypeptide and composition have significant clinical value.

The utility model relates to a sterilizing device for producing a sporopollen powder injection, which comprises a cylindrical sterilizing box, a multi-layer annular conveying component for conveying downwards is connected to the side wall of the sterilizing box, an inlet is formed in the top layer of the conveying component of the sterilizing box, an outlet is formed in the bottom layer of the conveying component, and both the inlet and the outlet are connected with a conveying line. And microwave generators are mounted at the top and the bottom of the disinfection box. According to the disinfection device for producing the agaricus bisporus powder injections, the disinfection time of the powder injections in the disinfection box is prolonged through the multiple layers of conveying assemblies in the disinfection box, meanwhile, the disinfection box is connected into the conveying line, continuous operation of disinfection and production is achieved, the production efficiency is not affected, and the disinfection quality is guaranteed.

The present application provides a kind of polypeptide, the polypeptide includes the sequence shown in any one of SEQ ID NO:1-8.The present application also provides a kind of composition, which includes the polypeptide of the sequence shown in SEQ ID NO:7, cefotaxime and sulbactam.The polypeptide of sequence SEQ ID NO:7 is strong in activity for inhibiting escherichia coli or listeria monocytogenes.The polypeptide is combined with cefotaxime sulbactam, and is strong in activity for inhibiting escherichia coli producing beta-lactamase.Therefore the polypeptide and composition have important clinical value.

The invention discloses a herba leonuri exosome-loaded hydrogel drug delivery system and a preparation method and application thereof, and relates to the technical field of medical materials, the drug delivery system comprises hydrogel and herba leonuri exosomes; cefotaxime is wrapped in the motherwort exosome; the hydrogel is prepared by crosslinking chitosan and sodium beta-glycerophosphate. The invention further discloses a preparation method of the drug delivery system and application of the drug delivery system in preparation of drugs for treating endometritis. Through double-layer entrapment slow release of the exosome and the temperature-sensitive hydrogel, the retention time of the cefotaxime in vivo is prolonged, the problem that the half-life period of the cefotaxime is short is solved, synergistic interaction is achieved through the anti-inflammatory effect of the motherwort exosome and the cefotaxime, the antibacterial effect is enhanced, and the temperature-sensitive hydrogel has high application value in treatment of endometritis.

The application belongs to the technical field of biological medicine, and specifically provides a cefotaxime acid and a continuous preparation method thereof. The method comprises the following steps: firstly, mixing 7-ACA suspension liquid with triethylamine solution; then, condensing the mixture with AE-active ester solution; then, extracting and separating the condensate liquid twice through an extraction separation device and methylene chloride back extraction to obtain an aqueous phase; reacting the aqueous phase with hydrochloric acid to obtain cefotaxime acid crystallization liquid; finally, taking part of the cefotaxime acid crystallization liquid to prepare seed crystal mixture liquid, adding the remaining cefotaxime acid crystallization liquid and crystallization solvent into the seed crystal mixture liquid at a specific speed to obtain cefotaxime acid. The method realizes continuous preparation of cefotaxime acid, significantly shortens the preparation period, improves the production efficiency, reduces the side reaction and product degradation, lays a foundation for preparing high-quality cefotaxime acid, and is beneficial to industrial production.

The present invention provides a preparation method of cefotaxime acid. The method uses 1-ethyl-2,3-dimethylimidazolium bromide or 1-butyl-2,3-dimethylimidazolium bromide as a catalyst, uses dichloromethane and isopropanol as solvents, reacts 7-ACA and AE-active ester in the presence of an appropriate amount of aqueous sodium bisulfite solution and triethylamine, after the reaction is completed, extracts with purified water, decolorizes the aqueous phase with activated carbon, filters, adds acetone, adjusts the pH for crystallization, and controls the crystallization temperature to obtain the target product cefotaxime acid. The preparation method of the present invention not only shortens the reaction time, but also reduces the impurity content, especially reduces the contents of impurity M and impurity N, and improves the product purity and yield. And this method has a simple process, has low requirements for equipment, has a simple post-treatment method, low cost, is convenient for industrial production, and has good application prospects.

The present invention provides a polypeptide comprising a sequence as set forth in any one of SEQ ID NOs: 1-8. Also provided is a composition comprising a polypeptide having a sequence as set forth in SEQ ID NO: 7, cefotaxime, and sulbactam. The polypeptide having a sequence as set forth in SEQ ID NO: 7 has strong activity in inhibiting Escherichia coli or Listeria monocytogenes. When used in combination with cefotaxime and sulbactam, the polypeptide has strong activity in inhibiting β-lactamase-producing Escherichia coli. Therefore, the polypeptide and composition have important clinical value.

The invention relates to the technical field of cefotaxime acid impurity control, and particularly discloses a method for controlling genotoxic impurities in cefotaxime acid. Carrying out water quenching and organic solvent extraction on reaction liquid obtained after the reaction of the 7-ACA and the AE active ester, and adjusting the pH value of the obtained water-phase feed liquid to be less than or equal to 7; and then adding a sulfur-loaded adsorbent for adsorption, carrying out solid-liquid separation, and crystallizing the obtained filtrate under an acidic condition to obtain the cefotaxime acid. According to the method provided by the invention, the existing cefotaxime acid synthesis step and crystallization step do not need to be specially set, and the content of 2-mercaptobenzothiazole in the cefotaxime acid product can be ensured to be below 3.0 ppm only by ensuring that the feed liquid before adsorption is an acidic aqueous phase solution and the content of 2-mercaptobenzothiazole in the feed liquid is below 0.5%. The method can be suitable for various cefotaxime acid synthesis processes with a water phase extraction step, is wide in application range, and can realize industrial production.

The present application belongs to the technical field of complex enzyme. The present application provides a beta-lactamase complex enzyme capable of degrading various antibiotics, and a fixing method and application thereof. The preparation method of the complex enzyme comprises the following steps: extracting gene fragments of CTX-M type broad-spectrum beta-lactamase and VIM type metal-beta-lactamase from Klebsiella pneumoniae; obtaining the target gene fragments through PCR amplification, and constructing into a basic vector to obtain a recombinant vector; transforming the recombinant vector into host cells for heterologous expression; and through protein induction, SDS-PAGE protein gel electrophoresis and protein purification, the complex enzyme is obtained. The complex enzyme successfully degrades penicillins such as ampicillin, carbapenems such as imipenem, cephalosporins such as cefotaxime and other beta-lactams. The complex enzyme gene is successfully expressed in Escherichia coli, and the optimal fixing condition is obtained. The beta-lactamase complex enzyme is fixed under the optimal fixing condition, and can be repeatedly used.

The application discloses a beta-lactamase and a gene for coding the beta-lactamase, and further discloses an expression cassette, a recombinant carrier, a recombinant cell or a recombinant bacteria, and a construction method of the recombinant bacteria, and further discloses the application of the beta-lactamase, the gene for coding the beta-lactamase, the expression cassette, the recombinant carrier, the recombinant cell or the recombinant bacteria, and the construction method of the recombinant bacteria in removing beta-lactam antibiotic pollution in the environment. The beta-lactamase gene is transformed into escherichia coli, so that the escherichia coli can hydrolyze beta-lactam antibiotics in the environment, including ampicillin, cefazolin, cefotaxime, imipenem and amikacin, and has great application value in eliminating beta-lactam antibiotic pollution in the environment.

The invention relates to a method for distinguishing the sensitive type of Escherichia coli to cefotaxime, which comprises the following steps: S1, acquiring Escherichia coli of different patients, detecting the sensitivity of each patient to cefotaxime, and then measuring Raman spectrum data, the Escherichia coli is detected to be sensitive and drug-resistant until the Escherichia coli is detected to be sensitive and drug-resistant from at least two patients; s2, selecting Raman spectrum data of Escherichia coli with measurement results of drug resistance and sensitivity, and setting a drug sensitivity label; s3, preprocessing the Raman spectrum data; s4, obtaining a classification model according to an AlexNet model; s5, inputting the processed Raman spectrum data and the drug sensitivity label into a classification model for training; s6, pretreating the detected escherichia coli, and collecting Raman spectrum data; and preprocessing the Raman spectrum data and inputting the preprocessed Raman spectrum data into the trained classification model to obtain the sensitive type of the detected escherichia coli. The method can be used for efficiently and accurately judging the sensitivity of the escherichia coli to the cefotaxime.

This invention provides the application of norzelamin in the preparation of NDM-1 enzyme inhibitors. Through cefotaxime hydrolysis assays, checkerboard minimum inhibitory concentration (MIC) tests, growth curves, bactericidal curves, hemolysis tests, and *Gnaphalium affine* infection experiments, it was demonstrated that norzelamin can inhibit NDM-1 enzyme activity and exhibits good synergistic antibacterial activity with the carbapenem antibiotic meropenem, enhancing the protective effect of meropenem against *Gnaphalium affine* larval infection models. Therefore, norzelamin, as a potential adjuvant for β-lactam antibiotics, can enhance the antibacterial effect of β-lactam antibiotics by inhibiting NDM-1 enzyme activity, which is of great significance for the clinical development of safe and effective β-lactam antibiotic adjuvants.